Published in Women's Health Weekly, April 22nd, 2000
The presentation outlined findings in a mouse model of breast cancer, indicating that vaccination with Avax's AC Vaccine technology resulted in improved relapse-free survival. The dosage regimen used in the animal experiments is very similar to that currently being used in the company's pivotal registration trial of M-Vax for metastatic melanoma and in Phase II studies of O-Vax for ovarian cancer.
This study was supported by a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.